public, even modest reductions in blood pressure through improved sleep, could result in important reductions in CVD at a population level.
In this randomized, investigator-blinded, controlled trial, we compared the efficacy of a web-delivered sleep intervention, Sleepio, in addition to cardiovascular risk factor education compared to cardiovascular risk factor education alone, in reducing mean 24-hour ambulatory blood pressure over 8 weeks through improvements in sleep quality. Sleepio is a multicomponent, web-delivered, educational, and behavioral sleep intervention proven to improve sleep in patients with chronic insomnia. [13] [14] [15] [16] 
METHODS

Study design and population
Sleep to Lower Elevated blood Pressure Trial (SLEPT) was a randomized, 2-group, parallel, investigator-blinded, controlled, single-center trial. The trial methods have previously been described in detail. 17 In brief, participants were recruited via local public screening events and media advertisements. Eligible participants were (i) aged ≥18 years, (ii) with mean blood pressure readings of 130-160/<110 mm Hg, (iii) self-reported sleeping difficulties within the previous 3 months (defined as usually taking more than 30 minutes to fall sleep and/or usually waking up more than once per night) and (iv) self-reported competency in using the internet. Our initial entry criteria included systolic blood pressure (SBP) readings of 140-160 mm Hg, later revised to SBP of 130-160 mm Hg. Exclusion criteria included (i) use of more than 2 antihypertensive medications at time of study entry or change in medication within past 2 months; (ii) history of myocardial infarction, ischemic stroke, or transient ischemic attack; (iii) history of congestive heart failure, dialysis, or diabetes; (iv) history of obstructive sleep apnea; (v) known sleep disorder [narcolepsy (G47.411, G47.419, G47.421, G47.429), hypersomnias (F51.11, F51.13, F51.19, G47.10-G47.14, G47.19), parasomnias including sleep walking, night terrors, recurring nightmares (F51.3, F51.4, F51.5, G47.50, G47.54, G47.59), periodic limb movements/restlessleg syndrome (G25.81, G47.61, G47.62); circadian rhythm sleep disorder (G47.20-G47.29)]; (vi) major or unstable depression or anxiety; (vii) ongoing substance abuse; and (viii) ongoing night shift work ( Figure 1 ).
Procedures
After provision of written informed consent, eligible participants were randomized between May 2013 and June 2014 using a centrally administered, computer-generated randomization scheme in a 1:1 allocation ratio. Randomly permuted blocks of varying size were used. Site investigators, data collectors, and statisticians were blinded to treatment-group assignment. On study enrollment, site investigators contacted the Sleepio team who controlled randomization and independently assigned the participant to the next available randomization number based on the randomization sequence. This process ensured that random allocation to treatment group was concealed from investigators. Participants randomized to the sleep intervention received an email of invitation to access the online sleep intervention through a unique code. Members of the Sleepio team held the central record of all participants who had been randomized along with treatment-group assignments and were not blinded to treatment-group assignment. To minimize contamination of control participants (i.e., seeking an intervention for sleep), consent forms and information leaflets stated that the trial was evaluating a multicomponent behavioral lifestyle intervention (face-to-face and web-delivered components) without detailing the sleep intervention. In addition, the control group received an educational intervention on cardiovascular risk factor modification.
Sleep intervention and usual care
Sleepio is a multicomponent online intervention consisting of sleep-hygiene education and cognitive behavioral therapy. It has shown improvements in measures of sleep quality, including sleep efficiency (proportion of time in bed spent sleeping), sleep-onset latency (time to fall asleep), and wakefulness after sleep onset (time spent awake at night after first falling asleep) in patients with primary insomnia. 13, 15, 16 Participants randomized to Sleepio underwent a standardized cognitive behavioral therapy program on lifestyle and environmental factors adversely affecting sleep, including practical steps to promote sleep and reduce wakefulness in bed (stimulus control) and techniques to improve sleep efficiency and ensure consistent sleep-wake schedules (sleeprestriction therapy). Cognitive therapy included teaching participants about techniques to reduce mental alertness, repetitive thoughts, and anxiety that can interfere with sleep. Participants could access an online daily sleep diary throughout the intervention and set automated text message or email reminders to complete the sleep diary. The online intervention was delivered in weekly sessions over 6-8 weeks by an animated virtual therapist. Members of the Sleepio team followed an email protocol for reminding participants who had not redeemed their voucher code to start the program; or if started, to resume if they had not accessed the program for more than 2 weeks during the treatment period. Additional details on measures to maximize adherence have been previously published. 17 Participants in both the intervention and control arms also received standard care, a vascular risk factor education session, delivered by specialist trained nurses in small groups over a 30-minute period prior to randomization. Components of the intervention included advice on smoking cessation, reducing alcohol intake, increasing physical activity levels, and adopting a healthy diet. This standardized session was administered in an identical fashion to participants in both trial arms.
Outcomes
The primary outcome was the difference in mean change in 24-hour ambulatory SBP after 8 weeks between intervention and control groups. Secondary outcomes included differences in mean change in: 24-hour ambulatory diastolic blood pressure (DBP), diurnal and nocturnal peak SBP and DBP, diurnal and nocturnal mean SBP and DBP, and measures of sleep quality and psychosocial health, including the Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index (PSQI), Sleep Condition Indicator (SCI), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI).
Statistical analysis
Based on a 2-sample comparison of means at a significance level of α = 0.05, power of 80% to detect a difference of 4 mm Hg between treatment arms (estimated minimum clinically meaningful difference), estimated SD for SBP reduction of 7.7 mm Hg and an estimated 5% loss to follow up, a per group sample size of 62 participants was required. [18] [19] [20] [21] Graphical and numerical summaries were generated for the primary and secondary outcomes and baseline participant characteristics. Mean 24-hour ambulatory blood pressure readings were calculated for each subject at baseline and follow up. This approach assumed equal structure of blood pressure readings over the 24-hour period of measurement. To account for this assumption, functional data analyses were used which analyzed each datum as a smooth function. 22 B-spline smoothing was used to represent each individual's discrete hourly measurements in functional form. The primary efficacy analysis included those participants who completed a minimum of one Sleepio session in the intervention group (54 of 67 participants randomized to Sleepio) and all 67 participants in the control group. For the primary analyses, the effect of the intervention on the change in mean 24-hour ambulatory blood pressure from baseline to follow-up was compared between groups using a t-test. Given the small sample size and increased risk of imbalance in baseline covariates between treatment groups, we completed secondary analyses modelling the effect of the intervention while adjusting for baseline characteristics using, (i) the mean response in a linear model and (ii) the functional representations in an analysis of variance for functional data. 23 The models adjusted for baseline SBP, age, sex, smoking status, caffeine consumption, alcohol consumption, physical activity, resting pulse, body mass index, sleep quality (PSQI, ISI, SCI), and psychosocial stress (BAI, BDI). Subgroup analyses were completed to determine whether a treatment effect differed by age, sex, severity of sleep impairment, and baseline SBP. All analyses were completed using R (version 3.2.1). The study was approved by the Research Ethics Committee at Galway University Hospital and all participants provided written informed consent. The study procedures were in accordance with the Helsinki Declaration. Figure 1 illustrates the flow of participants during the trial, with 67 participants randomized to the sleep intervention and 67 to control. Six participants in the sleep intervention arm and 1 participant in the control arm withdrew prior to study completion and did not return for the follow-up visit at 8 weeks. Data on the primary outcome at follow-up were missing for these 7 participants. Baseline characteristics are illustrated in Table 1 . The mean age was 59 years and 61% were female. Mean SBP at baseline was 143.0 mm Hg (SD 11.7) in the intervention arm and 141.1 mm Hg (SD 11.3) in the control arm.
RESULTS
Sleep quality
Participants in the sleep intervention group, compared to control participants, had significantly greater mean improvement in measures of sleep quality, including PSQI [difference in mean improvement 1.1; 95% confidence interval (CI), 0.1-2.2], ISI (2.8; 95% CI, 1.3-4.4), SCI (0.8; 95% CI, 0.2-1.4), and sleep efficiency (4.6; 95% CI, 0.7-8.5) ( Table 2) . Improvement in sleep quality was greatest in the subgroup of participants who participated in 3 or more online sleep intervention sessions, providing evidence of a dose response effect (P < 0.001). Antihypertensive medication was used by 25 (37.3%) of participants in the control group, compared to 19 (28.4%) in the sleep intervention group.
A small number of participants (4.5%) had changes to their antihypertensive medications during the trial (Supplementary eTable 1) .
Blood pressure
The mean change in 24-hour ambulatory SBP (primary outcome) over 8 weeks was not significantly different between intervention (0.9 mm Hg) and control (0.8 mm Hg) arms (Table 3) . Results were similar for average and peak SBP and DBP and 24-hour DBP. Subgroup analyses did not reveal an interaction in treatment effect (Supplementary eTable 2).
Adherence
Fifty-eight participants randomized to Sleepio activated the code to access the online sleep intervention. Of those who activated the online intervention, 93% (n = 54) completed 1 session, while 50% completed all 6 sessions. There was no difference in blood pressure improvement according to level of adherence to the intervention.
Psychosocial health
Participants in the sleep intervention group showed significantly greater mean improvement in measures of psychosocial health, including BDI (difference in mean improvement 2.0; 95% CI, 0.3-3.7) and BAI (1.4; 95% CI, 0.02-2.8) compared to control participants (Table 2) .
Sensitivity analysis
On multivariable analyses, adjusting for baseline covariates did not materially alter our findings for blood pressure, sleep quality, or psychosocial health.
DISCUSSION
In a population of community-dwelling individuals without CVD, a web-delivered sleep intervention significantly improved sleep quality and psychosocial health over shortterm follow-up, although no beneficial effect on blood pressure modification was demonstrated over 8 weeks.
Our study demonstrates that a simple, low-cost, webdelivered sleep intervention significantly improves sleep quality in participants that are representative of the general population. Previous studies investigating a sleep intervention have focused on populations with chronic primary insomnia, insomnia in cancer patients, insomnia in patients with stable heart failure and adult workers. 15, 16, [24] [25] [26] [27] [28] To our knowledge, this is the first study to demonstrate the feasibility of an online sleep intervention in modifying sleep quality in a general population with mild sleep impairment, providing a template for future studies evaluating the effect of sleep interventions on health outcomes. Improvements in sleep quality were evident across multiple measures, including the previously validated PSQI, ISI, and SCI scores, with a clinically meaningful change in mean SCI scores and PSQI scores in participants randomized to the sleep intervention. 15, 29 In our study, implementation of a sleep intervention did not result in short-term improvements in blood pressure control, despite improvements in sleep. There are a number of possible reasons for the absence of an observed blood pressure lowering effect. First, our primary hypothesis may be incorrect, in that there may not be a causal relationship between mild sleep impairment and blood pressure. It is plausible, for example, that the association between sleep impairment and blood pressure reported in prior observational studies may be due to confounding or reverse causation. Second, including participants with mild hypertension likely increased our risk of a false negative result, as the intervention may not be effective in participants with mild hypertension) (mean 24-hour ambulatory blood pressure in the intervention and control arms at study commencement was 138.0/83.5 and 136.8/82.5 mm Hg, respectively). While including a population with pre or mild hypertension reduced the risk of bias from changes in antihypertensive medications during the study, it also reduced the likelihood of demonstrating a treatment effect. It would be worthwhile evaluating this intervention in patients with higher baseline blood pressure. Similarly, our population included people with mild sleep impairment, which did improve with the intervention, but may have been insufficiently severe at baseline to contribute to increased blood pressure. A recent clinical trial in patients with more severe sleep disorder reported a beneficial effect on blood pressure through increased sleep duration over a 6-week period, although the difference in blood pressure reduction between intervention and control groups did not reach significance. 30 Third, our trial only evaluated the short-term effect of the intervention on blood pressure, and we are unable to comment on the effect over more extended follow-up. Accordingly, we assumed that the effect of changes in sleep manifest as short-term changes in blood pressure, which may not be correct. However, given sleep quality was successfully modified during the trial and the anticipated benefits of improved sleep quality on 24-hour Data were missing in the following participants: atrial fibrillation 5 (3.7%), nocturnal asthma 1 (0.8%), peripheral vascular disease 1 (0.8%). Weekly physical activity was categorized as: mainly sedentary (sitting, e.g., reading, watching television), mild exercise (minimal effort, e.g., easy walking, sport fishing, light gardening), moderate exercise (e.g., walking. bicycle riding, golf or yoga at least 4 hours per week), strenuous exercise (heart beats rapidly, e.g., running/jogging, football, vigorous swimming). Abbreviations: BAI, Beck anxiety inventory; BDI, Beck depression inventory; BMI, body mass index; DBP, diastolic blood pressure; ISI, insomnia severity index; PSQI, Pittsburgh sleep quality index; SBP, systolic blood pressure; SCI, sleep condition indicator. Due to incomplete follow-up data, the difference in means from baseline to week 8 and difference in mean change between intervention and control groups does not equal simple subtraction of the above scores. Due to incomplete follow-up data, the difference in means from baseline to week 8 and difference in mean change between intervention and control groups does not equal simple subtraction of the above scores.
blood pressure should be immediate (e.g., reduction in sympathetic activity and return of nocturnal dips in blood pressure), a longer intervention period would not be expected to alter our results. Fourth, only 50% of participants completed all 6 online sessions, which may have limited our ability to detect a treatment effect. We included a primarily older population, more than 40% of whom were retired. This population may have greater difficulty accessing and using an online intervention, compared to a younger population. Importantly, on sensitivity analysis, participation in a greater number of online sessions was not associated with greater reductions in blood pressure, over the 8-week period. Although our trial failed to demonstrate a short-term effect on blood pressure (primary outcome), we did observe significant improvements in measures of psychosocial health, namely depression and anxiety, in participants randomized to the sleep intervention, which were more apparent in the population who were adherent with the intervention. This is the first study to report improvements in psychosocial health in a general population of patients through an online sleep intervention and highlights its potential as a therapeutic intervention in patients with depression and anxiety. 31 The improvements were small. However, our trial was underpowered to determine clinically meaningful improvements in depression and anxiety scores and the proportion of participants with clinically significant depression or anxiety was low. Adequately powered randomized controlled trials will be required to determine if a sleep intervention can result in clinically meaningful improvements in these outcomes in relevant patient populations. Our findings also support evaluation of Sleepio in patients with cognitive impairment, where sleep impairment is common.
The strengths of our study include the completeness of data, low loss to follow (5.2%), use of 24-hour ambulatory measurements of blood pressure, and inclusion of a community-based cohort. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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